|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||261.38 - 264.80|
|52 Week Range||229.40 - 277.29|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||38.50|
|Earnings Date||Feb 02, 2022 - Feb 07, 2022|
|Forward Dividend & Yield||3.48 (1.42%)|
|Ex-Dividend Date||Sep 08, 2022|
|1y Target Est||273.18|
BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.
Becton Dickinson and Co (NYSE: BDX) will sell Accelerate Diagnostics Inc's (NASDAQ: AXDX) rapid testing solution for antibiotic resistance and susceptibility, offering results in hours versus one to two days with some traditional laboratory methods. Becton Dickinson will market and sell the Accelerate Pheno system and Accelerate Arc module and associated test kits through its global sales network. These solutions complement BD's existing Clinical Microbiology portfolio. The Accelerate PhenoTest
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...